Chapter 12 Liposome-Mediated Therapy of Neuroblastoma

Daniela Di Paolo, Monica Loi, Fabio Pastorino, Chiara Brignole, Danilo Marimpietri, Pamela Becherini, Irene Caffa, Alessia Zorzoli, Renato Longhi, Cristina Gagliani, Carlo Tacchetti, Angelo Corti, Theresa M. Allen, Mirco Ponzoni, Gabriella Pagnan

Research output: Contribution to journalArticlepeer-review


Neuroblastoma (NB) is the most common extracranial solid tumor in childhood and the most frequently diagnosed neoplasm during infancy. Despite of aggressive treatment strategies, the 5-year survival rate for metastatic disease is still less than 60% and, consequently, novel therapeutic approaches are needed. For increasing the therapeutic index of anticancer drugs, while reducing side effects, one of the most promising strategies in modern chemotherapy is based on the development of innovative drug delivery systems, such as liposomes. "Anticancer drug"-loaded liposomes have demonstrated enhanced ability to target to the affected area, as well as increased antitumor efficacy compared to conventional drugs. Liposomes tend to extravasate preferentially and to accumulate into tumor interstitial fluids, due to the defective structure of the new angiogenic vessels within the tumor masses. This inherent tumor selectivity can be increased further by coupling tumor-specific antibodies or other targeting moieties to the surface of the lipid envelope. Here, we describe the methodology used in these studies, as well as the antitumor results obtained by the use of several "anticancer drugs," encapsulated into antibody- and peptide-targeted liposomal formulations, against NB.

Original languageEnglish
Pages (from-to)225-249
Number of pages25
JournalMethods in Enzymology
Issue numberC
Publication statusPublished - 2009

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology


Dive into the research topics of 'Chapter 12 Liposome-Mediated Therapy of Neuroblastoma'. Together they form a unique fingerprint.

Cite this